Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant atezolizumab and adjuvant atezolizumab + bevacizumab with percutaneous radiofrequency ablation for small hepatocellular carcinoma
2020-000569-18Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Investigator-assessed recurrence-free survival at 2 years. Started Sep 2020; status: active.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-000569-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000569-18.